Get the Stockscreener App
1.19
0.83%
-0.01
After Hours:
1.23
0.04
+3.36%
Immunic Inc stock is traded at $1.19, with a volume of 851.52K.
It is down -0.83% in the last 24 hours and down -26.09% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.20
Open:
$1.23
24h Volume:
851.52K
Relative Volume:
1.34
Market Cap:
$108.55M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3469
EPS:
-3.43
Net Cash Flow:
$-71.16M
1W Performance:
-9.16%
1M Performance:
-26.09%
6M Performance:
-13.14%
1Y Performance:
+5.31%
1-Day Range:
$1.19
$1.255
1-Week Range:
$1.15
$1.33
52-Week Range:
$0.9451
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA
Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow
Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia
Immunic late-stage program for lead asset to proceed as planned - MSN
Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio
Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online
Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha
Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive financial news
Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch
Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de
Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq
FY2024 EPS Estimates for Immunic Lowered by Analyst - MarketBeat
Research Analysts Offer Predictions for Immunic Q4 Earnings - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully - Yahoo Canada Finance
Focus on long-term protection - European Biotechnology News
Stock Surge: Immunic Inc (IMUX) Closes at 1.40, Marking a 0.00 Increase/Decrease - The Dwinnex
Investing in Immunic Inc (IMUX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Marshall Wace LLP Has $44,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Renaissance Technologies LLC Has $323,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... - Yahoo Finance UK
Future of oral small molecule drugs – addressing potential in multiple sclerosis - European Pharmaceutical Review
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunic CMO on key ECTRIMS highlights and MS research - Proactive Investors USA
Get in on Immunic Inc’s (IMUX) buy-in window today! - SETE News
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IMAX (NYSE:IMAX) Stock Price Down 4.9% - Defense World
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World
What is the investor’s view on Immunic Inc (IMUX)? - US Post News
Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Hancock Whitney Corp Sells 2,958 Shares of Polaris Inc. (NYSE:PII) - Defense World
You might want to take a look at Inuvo Inc (INUV) now - SETE News
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Applied Fundamental Research LLC Decreases Stock Holdings in UFP Technologies, Inc. (NASDAQ:UFPT) - MarketBeat
UniQure rises on orphan drug status for genetic disorder gene therapy - XM
uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy - TipRanks
UFP Industries, Inc. (NASDAQ:UFPI) Holdings Decreased by Seven Eight Capital LP - Defense World
Unichem Laboratories Set To Discuss US Business Consolidation At Upcoming Board Meeting - NDTV Profit
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):